Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 4

1(50.0%)

Phase 3

1(50.0%)

2Total

Phase 4(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT05711732Recruiting

Busulfan Sample Collection Study

Role: lead

NCT05422131Completed

Clozapine Therapy Sample Collection - Method Comparison Study

Role: lead

NCT02055560Completed

Retrospective Evaluation of 5-FU Exposure Optimization in CRC Patients

Role: lead

NCT02376296Completed

Observational Study of Docetaxel Exposure in Metastatic Prostate Cancer Patients

Role: lead

NCT02502864Phase 4Completed

Multicenter Study of Pharmacokinetic-Guided Docetaxel in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide

Role: collaborator

NCT01326767Phase 3Completed

Central European Society for Anticancer Research (CESAR) Study of Paclitaxel Therapeutic Drug Monitoring

Role: collaborator

All 6 trials loaded